What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Sell
22
MYGN Quote, Financials, Valuation and Earnings
Last price:
$8.00
Seasonality move
:
3.17%
Day range:
$7.69 - $8.05
52-week range:
$7.35 - $29.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.86x
P/B ratio:
1.04x
Volume:
902.1K
Avg. volume:
988.6K
1-year change:
-60.98%
Market cap:
$725.9M
Revenue:
$837.6M
EPS (TTM):
-$1.41
Analysts' Opinion
-
Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 6 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $17.07, Myriad Genetics has an estimated upside of 114.7% from its current price of $8.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing -38.37% downside risk from its current price of $8.00.
Fair Value
-
According to the consensus of 10 analysts, Myriad Genetics has 114.7% upside to fair value with a price target of $17.07 per share.
MYGN vs. S&P 500
-
Over the past 5 trading days, Myriad Genetics has underperformed the S&P 500 by -8.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Myriad Genetics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Myriad Genetics has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Myriad Genetics reported revenues of $210.6M.
Earnings Growth
-
Myriad Genetics earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Myriad Genetics reported earnings per share of -$0.47.
Enterprise value:
663.1M
EV / Invested capital:
--
Price / LTM sales:
0.86x
EV / EBIT:
--
EV / Revenue:
0.79x
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-17.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$585.4M
Return On Assets:
-11.68%
Net Income Margin (TTM):
-15.2%
Return On Equity:
-17.13%
Return On Invested Capital:
-16.27%
Operating Margin:
-8.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $678.4M | $753.2M | $837.6M | $196.6M | $210.6M | |
| Gross Profit | $476.4M | $517M | $585.4M | $135M | $150.9M | |
| Operating Income | -$123.7M | -$144.6M | -$87.9M | -$30.4M | -$17.3M | |
| EBITDA | -$84.7M | -$197.4M | -$59.4M | -$16.3M | -$23.6M | |
| Diluted EPS | -$1.39 | -$3.20 | -$1.41 | -$0.36 | -$0.47 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $484.8M | $274.6M | $313.6M | $298M | |
| Total Assets | -- | $1.3B | $1.2B | $1.1B | $1B | |
| Current Liabilities | -- | $204.3M | $137.2M | $155.9M | $164.1M | |
| Total Liabilities | -- | $352.9M | $312.9M | $363.3M | $326.5M | |
| Total Equity | -- | $967.8M | $885.8M | $783.2M | $701.1M | |
| Total Debt | -- | -- | -- | $38.5M | $39.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$106.3M | -$110.9M | -$8.7M | -$54.7M | $6.6M | |
| Cash From Investing | -$77.5M | $31.9M | -$11.9M | -$12M | -$5.9M | |
| Cash From Financing | -$8M | $152.9M | -$7.4M | $121.9M | $2.1M | |
| Free Cash Flow | -$151.6M | -$184.2M | -$38.4M | -$68.2M | $700K | |
MYGN
Sector
Market Cap
$725.9M
$32.7M
Price % of 52-Week High
27.13%
39.31%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-60.76%
-48%
Beta (5-Year)
1.869
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.19
200-day SMA
Sell
Level
$19.04
Bollinger Bands (100)
Sell
Level
10.21 - 15.05
Chaikin Money Flow
Buy
Level
48.2M
20-day SMA
Sell
Level
$9.01
Relative Strength Index (RSI14)
Sell
Level
31.18
ADX Line
Sell
Level
41.75
Williams %R
Neutral
Level
-79.346
50-day SMA
Sell
Level
$10.90
MACD (12, 26)
Sell
Level
-0.83
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-67.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.853)
Buy
CA Score
(Annual)
Level (0.1757)
Buy
Beneish M-Score
(Annual)
Level (-3.0287)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.5941)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Stock Forecast FAQ
In the current month, MYGN has received 3 Buy ratings 6 Hold ratings, and 1 Sell ratings. The MYGN average analyst price target in the past 3 months is $17.07.
-
Where Will Myriad Genetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Myriad Genetics share price will rise to $17.07 per share over the next 12 months.
-
What Do Analysts Say About Myriad Genetics?
Analysts are divided on their view about Myriad Genetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Myriad Genetics is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Myriad Genetics's Price Target?
The price target for Myriad Genetics over the next 1-year time period is forecast to be $17.07 according to 10 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is MYGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Myriad Genetics is a Hold. 6 of 10 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MYGN?
You can purchase shares of Myriad Genetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Myriad Genetics shares.
-
What Is The Myriad Genetics Share Price Today?
Myriad Genetics was last trading at $8.00 per share. This represents the most recent stock quote for Myriad Genetics. Yesterday, Myriad Genetics closed at $8.00 per share.
-
How To Buy Myriad Genetics Stock Online?
In order to purchase Myriad Genetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Chewy a Growth Stock to Buy?
It might be a surprise to learn that during the…
Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Sell
42
KMX alert for Apr 12
CarMax [KMX] is up 2.87% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
Sell
30
CRSP alert for Apr 12
CRISPR Therapeutics AG [CRSP] is up 14.59% over the past day.
